Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA) Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA) Jennifer Thomas / Sunday, June 25, 2023 0 1638 Article rating: No rating Sunday, June 25, 2023 June 25, 2023 | Andreas Tiede, M.D., Ph.D.; Hannover Medical School; Hannover, Germany Read more
Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura Jennifer Thomas / Sunday, June 25, 2023 0 1057 Article rating: No rating Sunday, June 25, 2023 June 25, 2023 | Marie Scully, MBE, M.D.; University College London Hospitals; NHS Foundation Trust; London, U.K. Read more
A common, racially diverse protease activated receptor 4 functional variant impacts ischemic stroke outcomes: evidence for a pharmacogenetic effect A common, racially diverse protease activated receptor 4 functional variant impacts ischemic stroke outcomes: evidence for a pharmacogenetic effect Jennifer Thomas / Saturday, June 24, 2023 0 688 Article rating: No rating Saturday, June 24, 2023 June 24, 2023 | Frederik Roland Denorme, Ph.D.; University of Utah; Salt Lake City, UT, U.S. Read more
Oxygen versus ambient air in patients with intermediate-risk acute pulmonary embolism: The AIR randomized clinical trial Oxygen versus ambient air in patients with intermediate-risk acute pulmonary embolism: The AIR randomized clinical trial Jennifer Thomas / Saturday, June 24, 2023 0 977 Article rating: No rating Saturday, June 24, 2023 June 24, 2023 | David Jimenez, M.D., Ph.D.; Hospital Ramón y Cajal, Universidad de Alcalá, CIBERES; Madrid, Spain Read more